|
|
News Breaks | | | | March 22, 2013 | | 08:31 EDT |  | GILD | Gilead says CHMP adopts positive opinion for Stribild
Gilead Sciences announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for the once-daily, single tablet regimen Stribild for the treatment of HIV-1 infection in adult patients who are antiretroviral-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild. Stribild combines elvitegravir, an integrase inhibitor, and cobicistat, a pharmacoenhancing agent, with Truvada. The CHMP’s positive recommendation will be reviewed by the European Commission, which has the authority to approve medicines for use in the 27 countries of the European Union. Stribild has received marketing approval in the United States, Canada, South Korea and Australia. | |
|
News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. |
|
|
| May 21, 2013 | | 16:51 EDT | | GILD | Gilead's sofosbuvir gets EMA validation, now under assessment
 Subscribe for More Information | | | May 20, 2013 | | 07:34 EDT |  | GILD | UBS to host a conference
Subscribe for More Information | | | May 16, 2013 | | 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information | | | May 15, 2013 | | 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information | | | May 13, 2013 | | 09:39 EDT |  | GILD | Active equity option families trading
Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR | |
|
|
|
|
|
|
